The heart’s motion is so powerful that it can recharge devices that save our lives, according to new research from Dartmouth College. So, using a dime-sized invention developed by engineers at the Thayer School of Engineering at Dartmouth, the kinetic energy of the heart can be converted into electricity to power a wide-range of implantable devices, according to the study funded by the National Institutes of Health.
The possibility of complications and infections
“We’re trying to solve the ultimate problem for any implantable biomedical device;” says Dartmouth engineering professor John X.J. Zhang. “So, how do you create an effective energy source so the device will do its job during the entire life span of the patient; without the need for surgery to replace the battery?”
“Of equal importance is that the device not interfere with the body’s function,” adds Dartmouth research associate Lin Dong, first author on the paper. “We knew it had to be biocompatible, lightweight, flexible, and low profile; so it not only fits into the current pacemaker structure but is also scalable for future multi-functionality.”
So, the team’s work proposes modifying pacemakers to harness the kinetic energy of the lead wire that has attachment to the heart; converting it into electricity to continually charge the batteries. The added material is a type of thin polymer piezoelectric film; called “PVDF” and; when designed with porous structures — either an array of small buckle beams or a flexible cantilever — it can convert even small mechanical motion to electricity.
A self-charging pacemaker
Above all, researchers use the same potential modules as sensors; to enable data collection for real-time monitoring of patients. So, the results of the three-year study; completed by Dartmouth’s engineering researchers along with clinicians at UT Health San Antonio; were just published in the cover story for Advanced Materials Technologies.
Meanwhile, the two remaining years of NIH funding plus time to finish the pre-clinical process; and obtain regulatory approval puts a self-charging pacemaker approximately five years out from commercialization; according to Zhang.
“We’ve completed the first round of animal studies with great results which we are going to publish soon,” says Zhang. “However, there is already a lot of expressed interest from the major medical technology companies, and Andrew Closson; one of the study’s authors working with Lin Dong and an engineering PhD Innovation Program student at Dartmouth; is learning the business and technology transfer skills; to be a cohort in moving forward with the entrepreneurial phase of this effort.”